Intech Investment Management LLC purchased a new stake in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 14,658 shares of the company’s stock, valued at approximately $69,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SkyView Investment Advisors LLC lifted its position in 2seventy bio by 25.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock valued at $48,000 after purchasing an additional 2,500 shares during the period. Nisa Investment Advisors LLC acquired a new position in 2seventy bio in the second quarter valued at approximately $52,000. GSA Capital Partners LLP bought a new position in 2seventy bio in the third quarter valued at approximately $64,000. SG Americas Securities LLC acquired a new stake in 2seventy bio during the 3rd quarter worth $80,000. Finally, BBR Partners LLC grew its holdings in 2seventy bio by 66.7% during the 2nd quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock worth $96,000 after acquiring an additional 10,000 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.
2seventy bio Stock Up 3.5 %
TSVT stock opened at $3.53 on Monday. 2seventy bio, Inc. has a twelve month low of $2.29 and a twelve month high of $6.40. The company has a market cap of $182.11 million, a P/E ratio of -1.90 and a beta of 1.69. The business’s fifty day moving average is $4.39 and its 200-day moving average is $4.38.
2seventy bio Profile
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than 2seventy bio
- 3 Tickers Leading a Meme Stock Revival
- Guidewire Software Provides Long-Awaited Buying Opportunity
- 3 Small Caps With Big Return Potential
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- What is an Earnings Surprise?
- Fast-Growing Companies That Are Still Undervalued
Want to see what other hedge funds are holding TSVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 2seventy bio, Inc. (NASDAQ:TSVT – Free Report).
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.
